Physician profile
Robin E Kilpatrick
NPI 1871796557
$12,248.71
in general payments reported to CMS, 2019-2025
52 companies · $2,700 in 2025
The $2,700 reported for 2025 was more than what 82% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,306 · 2020: $1,486 · 2021: $1,568 · 2022: $1,371 · 2023: $1,618 · 2024: $2,201 · 2025: $2,700.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,459 · Education: $59.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,459.03 |
| Education | $59.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,394.20 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $1,389.89 | 2019-2025 | Tepezza, Evenity, Prolia |
| Corcept Therapeutics | $1,165.57 | 2019-2025 | Korlym |
| Lilly USA, LLC | $967.38 | 2019-2025 | Mounjaro, Zepbound, Humulin |
| Xeris Pharmaceuticals, INC. | $593.63 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Ibsa Pharma INC. | $562.64 | 2019-2025 | Tirosint, Licart, Flector |
| Abbott Laboratories | $522.66 | 2019-2025 | Freestyle Libre 3, Freestyle Libre |
| Alexion Pharmaceuticals, INC. | $453.57 | 2019-2024 | Strensiq |
| Radius Health, INC. | $442.44 | 2020-2025 | Tymlos |
| Abbvie INC. | $438.37 | 2019-2025 | |
| Amneal Pharmaceuticals LLC | $378.87 | 2019-2025 | Unithroid |
| Bayer Healthcare Pharmaceuticals INC. | $305.61 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $289.99 | 2019-2025 | |
| Kyowa Kirin, INC. | $283.51 | 2023-2025 | Crysvita |
| Boehringer Ingelheim Pharmaceuticals, INC. | $227.79 | 2019-2025 | Jardiance |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascendis Pharma Endocrinology INC | $212.40 | 2023-2025 | Yorvipath |
| Amarin Pharma, INC. | $208.19 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $193.43 | 2022-2025 | |
| Madrigal Pharmaceuticals | $188.40 | 2025 | Rezdiffra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $159.00 | 2019-2023 | Cycloset |
| Insulet Corporation | $153.06 | 2020-2025 | Omnipod |
| Ultragenyx Pharmaceutical INC. | $145.97 | 2020-2022 | |
| Astrazeneca Pharmaceuticals Lp | $121.73 | 2019-2022 | |
| Kvk-Tech, INC. | $115.05 | 2019 | |
| Neurocrine Biosciences, INC. | $111.60 | 2025 | |
| Recordati_rare_diseases_inc. | $90.57 | 2023-2025 | Isturisa, Signifor Lar |
| Becton, Dickinson and Company | $88.87 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $71.67 | 2020-2022 | |
| Sequel Med Tech, LLC | $70.53 | 2025 | Twiist |
| Rhythm Pharmaceuticals, INC. | $70.43 | 2025 | Imcivree |
| Valeritas, INC. | $69.65 | 2019 | |
| Nevro Corp. | $67.34 | 2023-2024 | Senza |
| Horizon Therapeutics Plc | $66.04 | 2022-2023 | Tepezza |
| Beta Bionics, INC. | $61.60 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Tolmar, INC. | $59.00 | 2025 | Jatenzo |
| Pfizer INC. | $56.98 | 2023-2024 | |
| Antares Pharma, INC. | $49.29 | 2023-2025 | Xyosted, Tlando, Nocdurna |
| Chiesi USA, INC. | $47.03 | 2025 | Mycapssa |
| Amryt Pharma Holdings Ltd | $41.74 | 2022 | |
| Averitas Pharma INC. | $38.76 | 2023-2025 | Qutenza |
| Dexcom, INC. | $37.96 | 2021-2025 | Dexcom G6 Transmitter |
| Medtronic, INC. | $37.22 | 2023-2024 | Minimed 780g, Minimed 770g |
| Companion Medical, INC. | $33.96 | 2019-2020 | |
| Soleno Therapeutics, INC. | $33.96 | 2025 | Vykat Xr |
| Blueprint Medicines Corporation | $23.39 | 2021 | |
| Tandem Diabetes Care, INC. | $23.07 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Cequr Corporation | $17.28 | 2025 | Cequr Simplicity |
| Acerus Pharmaceuticals Corporation | $15.07 | 2022 | |
| Halozyme INC | $13.29 | 2023 | |
| Clarus Therapeutics INC. | $13.20 | 2021 | |
| Amphastar Pharmaceuticals, INC. | $13.13 | 2024 | Baqsimi |
| Medtronic Minimed, INC. | $12.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Kilpatrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.